Edmond De Rotschild Investment Partners has led a EUR 23m series-C financing round for therapeutic antibody company PanGenetics. The round also included contributions from existing investors Index Ventures, Forbion Capital Partners and Credit Agricole Private Equity and new investors Biogen Idec New Ventures and Fortis Private Equity.
Fund, which has already been invested in at least one transaction, has a €1bn target
Pechel, via Pechel IV, and the co-investment team of Omnes back the French IT services firm
Connection Capital provided £6.7m to support the buyout of the business in 2017
Temasek previously led a £7m investment for the technology developer in 2016